GlassScriptPhysician profile
Aliya D Abdullah
NPI 1346069572
$2,124.45
in general payments reported to CMS, 2019-2025
15 companies · $2,124 in 2025
The $2,124 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,124.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $573.00 | 2025 | Evenity, Tavneos, Otezla |
| Janssen Biotech, INC. | $490.95 | 2025 | Tremfya, Simponi Aria |
| Alexion Pharmaceuticals, INC. | $226.07 | 2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $171.51 | 2025 | |
| Abbvie INC. | $138.58 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $127.71 | 2025 | Saphnelo |
| Ucb, INC. | $109.24 | 2025 | Bimzelx |
| Pfizer INC. | $74.03 | 2025 | |
| Mallinckrodt Hospital Products INC. | $60.09 | 2025 | Acthar |
| Scilex Pharmaceuticals INC. | $39.50 | 2025 | |
| Aurinia Pharma U.S., INC. | $35.40 | 2025 | Lupkynis |
| Alvogen INC | $22.40 | 2025 | Teriparatide |
| Pacira Pharmaceuticals Incorporated | $20.61 | 2025 | Zilretta |
| Glaxosmithkline, LLC. | $19.07 | 2025 | Benlysta |
| Radius Health, INC. | $16.29 | 2025 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Abdullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.